Filter By Category
Archives
Share on -
AVITRIPTAN
Generic Name: AVITRIPTAN
ABSTRACT -
Avitriptan is an investigational small-molecule 5-HT1B/1D receptor agonist in the triptan class studied for migraine treatment but not marketed for routine clinical use. Its molecular formula is C₂₂H₃₀N₆O₃S. The chemical representation above shows the 2D skeletal structure.
This document is for structured API information only. It is not a prescribing guide. Clinical use, if any, must follow the approved local label, trial protocol, and specialist medical supervision.
DOSAGE -
- Dosage should be determined only by a qualified healthcare professional.
- No approved public dosing regimen is established for routine clinical use unless specifically authorized in a local label.
- Clinical-study dosing, when applicable, is protocol-specific and must not be copied into routine practice.
- Do not administer outside an authorized clinical trial, compassionate-use pathway, or approved product labeling.
SIDE EFFECTS-
Possible side effects and safety concerns include:
- Tingling, warmth, flushing, chest or throat tightness, or pressure sensations
- Dizziness, fatigue, drowsiness, nausea, or dry mouth
- Blood-pressure elevation or palpitations may occur with triptan-class agents
- Serotonin-syndrome symptoms are rare but possible with serotonergic combinations
- Hypersensitivity reactions may occur
ALLERGIC REACTIONS -
Hypersensitivity to Avitriptan or related compounds/products may occur. Symptoms may include:
- Immediate urticaria, itching, flushing, or generalized rash
- Facial, lip, tongue, or throat swelling
- Wheezing, chest tightness, or breathing difficulty
- Dizziness, fainting, severe hypotension, or collapse
- Anaphylaxis, although uncommon, requires emergency medical treatment
Important: Patients who develop an allergic reaction to Avitriptan should seek immediate medical attention and inform all future healthcare providers of the allergy.
DRUG INTERACTIONS-
Avitriptan may interact with certain medicines, biologics, vaccines, protocols, or clinical conditions. Caution is needed with:
- SSRIs, SNRIs, MAO inhibitors, and other serotonergic medicines require review.
- Ergot derivatives or other triptans may increase vasospastic risk.
- Cardiovascular medicines and uncontrolled hypertension require specialist assessment.
- Patients should report all medicines, herbal products, and supplements.
Patients should inform healthcare providers about all prescription medicines, over-the-counter medicines, herbal products, vaccines, and supplements they are using.
PREAUTIONS–
- Avoid use in significant cardiovascular or cerebrovascular disease unless specifically evaluated.
- Do not use for hemiplegic or basilar-type migraine unless specialist-directed.
- Monitor for chest symptoms, neurologic changes, or serotonin-syndrome signs.
- Pregnancy and lactation safety are not established.
WARNINGS –
- Investigational status: safety and effectiveness for routine use may not be established.
- Serious or unexpected adverse events must be managed under protocol and reported promptly.
- Use only by personnel trained for the relevant formulation and administration route.
- Keep out of reach of children.
Share on -
. Developed by